A 2011 article published in Diabetes Care by C. Piccinni et al. titled “Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.” set out to “analyze the association between pioglitazone [(Actos)] use and bladder cancer through a spontaneous adverse event reporting system for medications.”
To obtain data for this study, the authors write “Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR).”
Results showed that “Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22)” and the relative risk found “was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82-6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs (6 and 4, respectively).”
That is, this study found that use of pioglitazone (Actos) raises the risk for bladder by 430% compared to non-users. Due to the fact that the manufacturer of Actos has failed time and again to adequately warn users of the risk for bladder cancer, a number of Actos bladder cancer lawsuits have been filed.
If you or a loved one used Actos and suffered bladder cancer as a result, you too may be entitled to significant financial compensation. For a free, no-obligation case consultation, contact our team of Actos bladder cancer lawyers at the information provided below. We have the compassion, experience, and resources required to win the justice you deserve.
Call today and see how we can help.
(855) 425 – 5529